Comparasion of Autogenic Inhibition and Reciprocal Inhibition Muscle Energy Techniques (METS) in Piriformis Syndrome
Launched by RIPHAH INTERNATIONAL UNIVERSITY · Jun 11, 2024
Trial Information
Current as of August 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different techniques called Autogenic Inhibition and Reciprocal Inhibition Muscle Energy Techniques (METS) to see which one works better for people with Piriformis Syndrome. Piriformis Syndrome is a condition that causes pain in the buttock and can make it hard to sit comfortably or move your hips. The researchers want to find out how effective these techniques are in relieving pain and improving movement for patients.
To participate in this study, individuals must be between the ages of 25 and 45 and have been diagnosed with Piriformis Syndrome through specific tests. They should be experiencing hip pain that is moderate (rated between 3-6 on a pain scale), have had buttock pain for at least three months, and find it painful to sit for longer than 20 minutes. However, people with hip joint problems, trauma history, certain medical conditions, or who are pregnant are not eligible to join. Participants will receive one of the muscle energy techniques and will be closely monitored to see how it helps with their symptoms.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Both genders with ages between 25-45 years.
- • Patients diagnosed with Piriformis syndrome using the Piriformis FAIR test, Freiberg test, Lasegue test, Beaty test, and pace sign.
- • Hip pain with a threshold of NPRS 3-6.
- • Limited ROM of Hip Internal Rotation and Abduction measured using a goniometer.
- • Buttock pain ≥ 3 months.
- • Pain with prolonged sitting (more than 20 minutes)
- Exclusion Criteria:
- • Hip Degenerative changes.
- • History of Trauma or Fracture
- • Other Systemic Conditions
- • Postural abnormality/deformity
- • Diagnosed Psychological Disorders
- • Pregnancy
About Riphah International University
Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rawalpindi, Punjab, Pakistan
Patients applied
Trial Officials
Rabiya Noor, PhD
Principal Investigator
Riphah International University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported